poly(ADP-ribose) polymerase inhibitors

PARylation as a Mediator of Epigenetic Remodelling: Integrating DNA Methylation, Oxidative Stress and Inflammation in Human Disease

PARylation, a post-translational modification catalyzed by PARP-1, represents a central mechanism connecting oxidative stress, inflammation, and epigenetic regulation of gene expression.

Informazioni

Struttura
Spin OFF
KET
Keywords
Progetti principali
Altre informazioni

Componenti del gruppo

Nome	E-mail

Collaboratori nazionali ed internazionali

Laboratori

Pubblicazioni

Brevetti

Progetti di ricerca

ERC

ERC	Descrizione

Infrastrutture

Leggi tutto su PARylation as a Mediator of Epigenetic Remodelling: Integrating DNA Methylation, Oxidative Stress and Inflammation in Human Disease

Rucaparib. An emerging parp inhibitor for treatment of recurrent ovarian cancer

Recently, Poly-ADP-Ribose Polymerase (PARP) inhibitors are one of the most intensively studied group of antiblastic agents for the management of recurrent ovarian cancer. Among this family, Olaparib was the first to be approved by European Medicines Agency as maintenance therapy post-response to platinum-based chemotherapy for recurrent ovarian cancer in women with deleterious BRCA1/2 mutation. Following that, the Food and Drug Administration (FDA) approved Olaparib monotherapy as fourth or later line of treatment in advanced ovarian cancer with deleterious germ-line BRCA1/2 mutation.